SCOLR Expects New Licensing Agreement This Year
This article was originally published in The Tan Sheet
Executive Summary
SCOLR Pharma says it could have a new licensing agreement for an extended release ibuprofen product made with its patented Controlled Delivery Technology by September of this year
You may also be interested in...
SCOLR Ready To Answer FDA Questions On 12-Hour Pseudoephedrine ANDA
FDA has raised questions on "minor" issues regarding SCOLR Pharma's proposed nonprescription 12-hour pseudoephedrine tablet, according to the firm
SCOLR Ready To Answer FDA Questions On 12-Hour Pseudoephedrine ANDA
FDA has raised questions on "minor" issues regarding SCOLR Pharma's proposed nonprescription 12-hour pseudoephedrine tablet, according to the firm
SCOLR Ready To Answer FDA Questions On 12-Hour Pseudoephedrine ANDA
FDA has raised questions on "minor" issues regarding SCOLR Pharma's proposed nonprescription 12-hour pseudoephedrine tablet, according to the firm